154 related articles for article (PubMed ID: 32075300)
1. Addition of Partial Envelope Domain II into Envelope Domain III of Dengue Virus Antigen Potentiates the Induction of Virus-Neutralizing Antibodies and Induces Protective Immunity.
Park J; Lee HY; Khai LT; Thuy NTT; Mai LQ; Jang YS
Vaccines (Basel); 2020 Feb; 8(1):. PubMed ID: 32075300
[TBL] [Abstract][Full Text] [Related]
2. A novel chimeric dengue vaccine candidate composed of consensus envelope protein domain III fused to C-terminal-modified NS1 protein.
Huang HJ; Yang M; Chen HW; Wang S; Chang CP; Ho TS; Kao YS; Tien SM; Lin HH; Chang PC; Lai YC; Hsiao YP; Liu YL; Chao CH; Anderson R; Yeh TM; Lin YS; Wan SW
Vaccine; 2022 Apr; 40(15):2299-2310. PubMed ID: 35287985
[TBL] [Abstract][Full Text] [Related]
3. Recombinant Protein Mimicking the Antigenic Structure of the Viral Surface Envelope Protein Reinforces Induction of an Antigen-Specific and Virus-Neutralizing Immune Response Against Dengue Virus.
Kim J; Lim TY; Park J; Jang YS
J Microbiol; 2023 Jan; 61(1):131-143. PubMed ID: 36723792
[TBL] [Abstract][Full Text] [Related]
4. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
[TBL] [Abstract][Full Text] [Related]
5. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
[TBL] [Abstract][Full Text] [Related]
6. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
[TBL] [Abstract][Full Text] [Related]
7. Development of a monoclonal antibody specific to envelope domain III with broad-spectrum detection of all four dengue virus serotypes.
Kim SH; Kim YN; Truong TT; Thu Thuy NT; Mai LQ; Jang YS
Biochem Biophys Res Commun; 2016 May; 473(4):894-898. PubMed ID: 27059141
[TBL] [Abstract][Full Text] [Related]
8. Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice.
Watanabe S; Chan KW; Wang J; Rivino L; Lok SM; Vasudevan SG
J Virol; 2015 Jun; 89(11):5847-61. PubMed ID: 25787279
[TBL] [Abstract][Full Text] [Related]
9. Oral immunisation of mice with transgenic rice calli expressing cholera toxin B subunit fused to consensus dengue cEDIII antigen induces antibodies to all four dengue serotypes.
Kim MY; Kim BY; Oh SM; Reljic R; Jang YS; Yang MS
Plant Mol Biol; 2016 Oct; 92(3):347-56. PubMed ID: 27566485
[TBL] [Abstract][Full Text] [Related]
10. Epitope Presentation of Dengue Viral Envelope Glycoprotein Domain III on Hepatitis B Core Protein Virus-Like Particles Produced in
Pang EL; Peyret H; Ramirez A; Loh HS; Lai KS; Fang CM; Rosenberg WM; Lomonossoff GP
Front Plant Sci; 2019; 10():455. PubMed ID: 31057572
[TBL] [Abstract][Full Text] [Related]
11. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
[TBL] [Abstract][Full Text] [Related]
12. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
[TBL] [Abstract][Full Text] [Related]
13.
Shukla R; Rajpoot RK; Arora U; Poddar A; Swaminathan S; Khanna N
Front Microbiol; 2017; 8():2644. PubMed ID: 29367852
[TBL] [Abstract][Full Text] [Related]
14. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
[TBL] [Abstract][Full Text] [Related]
15. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
[TBL] [Abstract][Full Text] [Related]
16. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
[TBL] [Abstract][Full Text] [Related]
17. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
[TBL] [Abstract][Full Text] [Related]
18. Computational analysis of perturbations in the post-fusion Dengue virus envelope protein highlights known epitopes and conserved residues in the Zika virus.
Chakraborty S
F1000Res; 2016; 5():1150. PubMed ID: 27540468
[TBL] [Abstract][Full Text] [Related]
19. Generation and characterization of cross neutralizing human monoclonal antibody against 4 serotypes of dengue virus without enhancing activity.
Injampa S; Muenngern N; Pipattanaboon C; Benjathummarak S; Boonha K; Hananantachai H; Wongwit W; Ramasoota P; Pitaksajjakul P
PeerJ; 2017; 5():e4021. PubMed ID: 29152418
[TBL] [Abstract][Full Text] [Related]
20. Structure-based evaluation of the envelope domain III-nonstructural protein 1 (EDIII-NS1) fusion as a dengue virus vaccine candidate.
Shoushtari M; Rismani E; Salehi-Vaziri M; Azadmanesh K
J Biomol Struct Dyn; 2024 Feb; ():1-19. PubMed ID: 38319049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
